A former Roche employee has been appointed to vice president of clinical research and development at Synosia Therapeutics. Dr Uwe Meya is based at the company's Swiss office in Basel.
Powder characterisation firm Freeman Technology has made its first direct appointment in the US. Jon Yin (below) joins as application specialist and will develop technical support for the company.
Molecular Profiles, a contract research services provider to the pharma and biopharma sectors, has expanded its scientific panel with the arrival of Professor Lisbeth Illum (below). She has over 25 years" pharma iustry experience.
One of the only institutes to bring six of its cancer drug discoveries to market has appointed Dr Vladimir Yamshchikov. He joins as director of infectious disease at Scientific Research's research department in Birmingham, Alabama. The organisation will benefit from Yamshchikov's scientific, technical and regulatory knowledge.
Retired Pfizer senior vice president John Mitchell joins NMT's scientific advisory board, bringing with him pharmaceutical industry expertise. Joining him is Professor Dr Siegfried Neumann - a senior consultant of R&D at Merck KGaA.
Johan Thans is the new managing director of northwest Europe at Schoeller Arca Systems. He is based at the firm's European headquarters in Hardenburg, Holland, but will spend a large part of his time working with local managers in the UK.
Pfizer Centresource, a leading global supplier of active pharmaceutical ingredients (APIs) and dosage form manufacturing, has named Jeff Frazier (below) as vice president of its fine chemical division. His responsibilities include marketing and business support.
Hakan Ekstrand is the new managing director for Tapflo, a developer and manufacturer of pumps for industrial applications. Formerly an export manager, Ekstrand has worked at Tapflo since 1992.
Metal detection specialist Lock Inspection Systems, is strengthening its position in the pharma industry with the arrival of new marketing manager Simon Taylor. His responsibilities cover the UK and export sales.
Astute Medical's ceo Christopher Hibberd has joined the Oxford Genome Sciences board of directors. He will support the development of a portfolio of antibody products to diagnose and treat cancer